Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 1

Status

Unknown 2Terminated 1Completed 1

Sponsor Class

OTHER 172INDUSTRY 30NIH 19OTHER_GOV 4NETWORK 3FED 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 3Plasma cell 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 3Recurrence 1Neoplasms, Plasma Cell 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Capecitabine 28apatinib 25Oxaliplatin 24Cisplatin 24tislelizumab 23Gemcitabine 23Irinotecan 19Paclitaxel 18Carboplatin 18Docetaxel 15Bevacizumab 15Fluorouracil 14Drug Therapy 13Cyclophosphamide 11pembrolizumab 10camrelizumab 10Vinorelbine 9Radiation 9S 1 (combination) 8Leucovorin 8Cetuximab 8toripalimab 7sintilimab 7Rituximab 7Erlotinib Hydrochloride 7pyrotinib 6Gefitinib 6Albumin-Bound Paclitaxel 6fludarabine 5anlotinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × OTHER_GOV × Azacitidine × Clear all
NCT03493646 2024-05-28

Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486

Kirby Institute

Phase 2 Completed
40 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06105658 2023-10-30

Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML

Anhui Provincial Hospital

Phase 2 Unknown
20 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02275663 2015-01-06

Azacytidine Plus FLAG for Relapsed or Refractory AML

King Fahad Medical City

Phase 2 Unknown
37 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00412919 2013-12-16

Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma

Bayside Health

Phase 2 Terminated
7 enrolled
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡